ESPOO, Finland--(BUSINESS WIRE)--Mobidiag Ltd, a Finnish molecular diagnostics company, today announced the opening of a new office in United Kingdom and the appointment of Stuart Cranmer as Managing Director to lead the business in one of the most strategic markets for Mobidiag. In addition to offices in Finland (headquarters), France and Sweden, Mobidiag UK will play a key role in accelerating the company’s growth locally and leveraging its global coverage.
“For the past months, we have seen a growing interest for our IVD products in UK. The UK is well known for its world-leading laboratories and hospitals, and was clearly a strategic target for developing the Mobidiag business. Our goal is to make the Amplidiag® platform and assay systems more accessible in the UK and be able to support our customers better with local support. Stuart Cranmer who will be leading the new UK office, has many years’ experience in the market and is ideally suited to help us achieve this goal” said Tuomas Tenkanen, CEO at Mobidiag.
“There has been a very positive response to the introduction of Mobidiag’s products in the UK and we are excited at the prospects going forward. The portfolio of existing and pending products has many unique characteristics that are ideally suited to the UK market and we are certain that the customer will appreciate the value they bring” said Stuart Cranmer,
About Mobidiag Ltd.
Established in 2000, Mobidiag develops innovative solutions to advance the diagnosis of infectious diseases and serves the European clinical diagnostics market since 2008. Mobidiag is headquartered in Espoo, Finland.
Mobidiag addresses both high to medium volume screening with the new Amplidiag® Easy platform, bringing the Amplidiag® suite further by automating the workflow from sample to results, and the upcoming Novodiag® platform & associated panels for a fully automated solution and suitable for smaller volumes and labs. Visit www.mobidiag.com.